Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Medicine  11, 837 - 844 (2005)
Published online: 17 July 2005; | doi:10.1038/nm1272

The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy

Monika Buitrago1, 2, Kristina Lorenz2, Alexander H Maass3, Silke Oberdorf-Maass1, Ursula Keller1, Eva M Schmitteckert2, Yuri Ivashchenko4, Martin J Lohse2 & Stefan Engelhardt1

1  Rudolf-Virchow-Center/DFG-Research Center for Experimental Biomedicine, University of Wuerzburg, Versbacher Strasse 9, 97078 Wuerzburg, Germany.

2  Institute of Pharmacology and Toxicology, University of Wuerzburg, Versbacher Strasse 9, 97078 Wuerzburg, Germany.

3  Medizinische Universitaetsklinik, University of Wuerzburg, Josef-Schneider-Strasse 2, 97080 Würzburg, Germany.

4  Sanofi-Aventis, Cardiovascular Division, Industriepark Höchst H823, 65926 Frankfurt am Main, Germany.

Correspondence should be addressed to Stefan Engelhardt stefan.engelhardt@virchow.uni-wuerzburg.de

Hypertrophy represents the major physiological response of the heart to adapt to chronically enhanced workload, but is also crucial in the development of heart failure. Although we know of numerous inducers of cardiac hypertrophy, little is known about mechanisms that limit cardiac hypertrophy. Here, we describe the transcriptional repressor NAB1 as an endogenous regulator of cardiac growth. We identified NAB1 as being upregulated in both mouse and human heart failure. Nab1 is highly expressed in mammalian cardiac myocytes and it inhibited cardiomyocyte hypertrophy through repression of its targets, transcription factor Egr. Transgenic mice with cardiac-specific overexpression of Nab1 showed that Nab1 is a potent inhibitor of cardiac growth in response to pathological stimuli in vivo. Nab1 overexpression suppressed adrenergically induced and pressure overload−induced hypertrophy, whereas physiological growth during development and in response to exercise was not affected. These findings implicate the Nab1-Egr1 axis as a crucial regulator of pathological cardiac growth.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Suppressing a sick heart

Nature Medicine News and Views (01 Aug 2005)

Calcineurin?the missing link in cardiac hypertrophy

Nature Medicine News and Views (01 Jun 1998)

See all 5 matches for News And Views
 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

Open Innovation Challenges

Competing financial interests
Figures & Tables
Supplementary info
See also: News and Views by Khachigian
Export citation
natureproducts

Search buyers guide:

 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2005 Nature Publishing Group | Privacy policy